ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None2022202120202019201820172016 November 28, 2022 Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference November 14, 2022 Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates November 14, 2022 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) November 8, 2022 Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th November 8, 2022 Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022 October 22, 2022 Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting October 12, 2022 Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 30
Year None2022202120202019201820172016 November 28, 2022 Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference November 14, 2022 Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates November 14, 2022 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) November 8, 2022 Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th November 8, 2022 Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022 October 22, 2022 Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting October 12, 2022 Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 30
November 14, 2022 Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 14, 2022 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
November 8, 2022 Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
November 8, 2022 Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
October 22, 2022 Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
October 12, 2022 Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock